{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["durvalumab","olaparib"],["durvalumab","cediranib"],["durvalumab","olaparib","cediranib"]],"indication":"advanced solid tumors","name":"NCT02484404","nct_id":"NCT02484404","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02484404. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Ph I Durvalumab + cediranib dose escalation","label":"P1 Durvalumab+C","type":"EXPERIMENTAL"},{"description":"Ph I Durvalumab + olaparib dose escalation","label":"P1 Durvalumab+O","type":"EXPERIMENTAL"},{"description":"Ph I Durvalumab + olaparib + cediranib dose escalation","label":"P1 Durvalumab+O+C","type":"EXPERIMENTAL"},{"description":"Ph II Durvalumab + cediranib at RP2D","label":"P2 Durvalumab+C","type":"EXPERIMENTAL"},{"description":"Ph II Durvalumab + olaparib at RP2D","label":"P2 Durvalumab+O","type":"EXPERIMENTAL"},{"description":"Ph II Durvalumab + olaparib + cediranib at RP2D","label":"P2 Durvalumab+O+C","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-10-30","type":"ESTIMATED"},"conditions":["Colorectal Neoplasms","Breast Neoplasms"],"enrollment":{"count":268,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Olaparib","otherNames":[],"type":"DRUG"},{"name":"Cediranib","otherNames":[],"type":"DRUG"},{"name":"Durvalumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-10","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-10-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Ph II Determine overall response rate of Durvalumab-O and Durvalumab-C in patients with recurrent ovarian cancer","timeFrame":"every 4 wks for toxicity and every 8 wks for response"},{"measure":"Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors","timeFrame":"28 days"}],"references":[{"citation":"Fialkoff G, Takahashi N, Sharkia I, Gutin J, Hermoni N, Nirula M, Kumar R, Pongor L, Nichols S, Sciuto L, Parmar K, Desai P, Suresh P, Abel M, El Meskini R, Maoz M, Rottenberg Y, Nevo S, Nechushtan H, Peretz T, Roame D, Hubert A, Cohen JE, Salah A, Temper M, Grinshpun A, Weaver-Ohler Z, Rajan A, Figg WD Sr, Zick A, Sadeh R, Friedman N, Thomas A. Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. J Clin Invest. 2026 Oct 1;136(19):e202151. doi: 10.1172/JCI202151. eCollection 2026 Oct 1.","pmid":"42820295","type":"DERIVED"},{"citation":"Santiago-Sanchez G, Rosato F, Fabian KP, Padget MR, Lee JM, Karzai F, Schlom J, Gulley JL, Hamilton DH, Lee JK, Pruitt MR, Bayliffe A, Su Z, Moisan J, Katragadda M, Hodge JW. PARP inhibition combined with a T-cell receptor beta chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression. J Immunother Cancer. 2026 Jul 1;14(7):e014518. doi: 10.1136/jitc-2025-014518.","pmid":"42386344","type":"DERIVED"},{"citation":"Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, Shrestha R, Aragon-Ching JB, Goswami M, Donahue RN, Cordes LM, Baj A, Seo CCY, Terrigino NT, Bright JR, Hennigan ST, King IM, Trostel SY, Fenimore JM, Liu Y, Calzone KA, Schlom J, Gulley JL, Dahut WL, Figg WD, Sowalsky AG, Lee JM, Karzai F. Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2026 Mar 25;14(3):e014365. doi: 10.1136/jitc-2025-014365.","pmid":"41881502","type":"DERIVED"},{"citation":"Fujii T, Cimino-Mathews A, Lipkowitz S, Lee MJ, Nair J, Solarz BB, Zimmer A, Redd B, Levy EB, Rastogi S, Sato N, McCoy A, Steinberg SM, Lee JM. A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation. Cancer Med. 2025 Dec;14(23):e71220. doi: 10.1002/cam4.71220.","pmid":"41360639","type":"DERIVED"},{"citation":"Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3.","pmid":"31345267","type":"DERIVED"},{"citation":"Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marte J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.","pmid":"30514390","type":"DERIVED"}],"start_date":{"date":"2015-06-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","url":"https://clinicaltrials.gov/study/NCT02484404"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02484404"}